The Burzynski Clinic is a medical clinic in Texas, United States founded in 1976 and offering unproven cancer treatment. It is best known for the controversial "antineoplaston therapy", a chemotherapy using compounds it calls antineoplastons, devised by the clinic's founder Stanislaw Burzynski in the 1970s.
The clinic has been the focus of criticism primarily due to the way its antineoplaston therapy is promoted, the costs for cancer patients participating in "trials" of antineoplastons, problems with the way these trials are run, and legal cases brought as a result of the sale of the therapy without state board approval. Additionally, there is no accepted scientific evidence of clinical efficacy of antineoplaston combinations for various diseases.
Burzynski was born on January 23, 1943 in Lublin, Poland. On graduating with Distinction at age 24 from the Medical Academy in Lublin, he had published fourteen papers. The following year he earned a Ph.D. in biochemistry.
Burzynski moved to the United States in 1970, working at Baylor College until 1977, when he established the Burzynski Research Laboratory where he administered antineoplaston therapy, initially to 21 patients but then more widely as "experimental" treatment. This opened him up to "charges of unethical conduct and to the suspicion he had become a merchant of false hope", which led to several instances of media controversy.:138
Burzynski founded the Burzynski Research Institute in 1984. His scientific papers have caused academic controversy, with reviewers disputing the design of the trials and scientific validity of the published results.
Antineoplaston therapy has been offered in the U.S. since 1984 but is not approved for general use. The compounds are not licensed as drugs but are instead sold and administered as part of clinical trials at the Burzynski Clinic and the Burzynski Research Institute.
Burzynski stated that he began investigating the use of antineoplastons after detecting what he considered significant differences in the presence of peptides between the blood of cancer patients and a control group. He first identified antineoplastons from human blood. Since similar peptides had been isolated from urine, early batches of Burzynski's treatment were isolated from urine. Burzynski has since produced the compounds synthetically.
The first active peptide fraction identified was called antineoplaston A-10 (3-phenylacetylamino-2,6-piperidinedione). From A-10, antineoplaston AS2-1 was derived – a 4:1 mixture of phenylacetic acid and phenylacetylglutamine. The Burzynski Clinic website states that the active ingredient of antineoplaston A10-I is phenylacetylglutamine.
Since 2011, the clinic has marketed itself as offering "personalized gene-targeted cancer therapy" which stirred further controversy as the treatment bears no relationship to gene-targeted therapy and only superficially incorporates elements of personalized medicine. The clinic's version of personalized medicine bears little resemblance to targeted cancer therapy, as the clinic includes chemotherapy drugs and antineoplastons are part of this treatment.
According to the National Cancer Institute, as of April 2013, "no phase III randomized, controlled trials of antineoplastons as a treatment for cancer have been conducted. Publications have taken the form of case reports, phase I clinical trials, toxicity studies, and phase II clinical trials", and "for the most part, these publications have been authored by the developer of the therapy, Dr. Burzynski, in conjunction with his associates at the Burzynski Clinic. Although these studies often report remissions, other investigators have not been successful in duplicating these results."
Since the mid-1990s, Burzynski registered some sixty clinical trials of antineoplastons and, in December 2010, a Phase III trial which did not open for patient recruitment. Burzynski has not published full results for any of these. According to his lawyer, Richard Jaffe:
[...] Burzynski personally put together seventy-two protocols to treat every type of cancer the clinic had treated and everything Burzynski wanted to treat in the future. [...] We heard that the FDA had to put together a fifty-person task force to review all of the protocols Burzynski submitted.
All trials were paused (no new patients allowed) following a 2013 FDA inspections which found (for the third consecutive time) significant issues with his Institutional Review Board, and, according to papers published in November 2013, substantial issues with the conduct of both the clinic and Burzynski as principal investigator.
Although Burzynski and his associates claim success in the use of antineoplaston combinations for the treatment of various diseases, and some of the clinic's patients say they have been helped, there is no evidence of the clinical efficacy of these methods. The consensus among the professional community, as represented by the American Cancer Society and Cancer Research UK among others, is that antineoplaston therapy is unproven and the overall probability of the treatment turning out to be as claimed is low due to lack of credible mechanisms and the poor state of research after more than 35 years of investigation. While the antineoplaston therapy is marketed as a non-toxic alternative to chemotherapy, it is a form of chemotherapy with significant known side effects including severe neurotoxicity.
Independent scientists have been unable to reproduce the positive results reported in Burzynski's studies: NCI observed that researchers other than Burzynski and his associates have not been successful in duplicating his results, and Cancer Research UK states that "available scientific evidence does not support claims that antineoplaston therapy is effective in treating or preventing cancer."
There is no convincing evidence from randomized controlled trials in the scientific literature that antineoplastons are useful treatments of cancer, and the U.S. Food and Drug Administration (FDA) has not approved these products for the treatment of any disease. The American Cancer Society has stated since 1983 that there is no evidence that antineoplastons have any beneficial effects in cancer and recommended that people do not buy these products since there could be serious health consequences. A 2004 medical review described antioneoplaston treatment as a "disproven therapy".
In 1998, three oncologists were enlisted by the weekly Washington newsletter The Cancer Letter to conduct independent reviews of Burzynski's clinical trial research on antineoplastons. They concluded that the studies were poorly designed, not interpretable, and "so flawed that it cannot be determined whether it really works". One of them characterized the research as "scientific nonsense". In addition to questioning Burzynski's research methods, the oncologists found significant and possibly life-threatening toxicity in some patients treated with antineoplastons.
According to the American Cancer Society, "Treatment can cost from $7,000 to $9,500 per month or more, depending on the type of treatment, number of consultations, and the need for surgery to implant a catheter for drug delivery. Available information suggests that health insurance plans often do not reimburse costs linked to this treatment." As of March 2015, the Burzynski Clinic required patients to provide a deposit before treatment starts and their website informed patients that "Since we are classified as "out of network" we are unable to accept Medicare, Medicaid and any HMO insurance".
Burzynski's use and advertising of antineoplastons as an unapproved cancer therapy were deemed to be unlawful by the U.S. FDA and the Texas Attorney General, and limits on the sale and advertising of the treatment were imposed as a result.
In 2009, the FDA issued a warning letter to the Burzynski Research Institute, stating that an investigation had determined the Burzynski Institutional Review Board (IRB) "did not adhere to the applicable statutory requirements and FDA regulations governing the protection of human subjects." It identified a number of specific findings, among them that the IRB had approved research without ensuring risk to patients was minimized, had failed to prepare required written procedures or retain required documentation, and had failed to conduct required continuing reviews for studies, among others. The Institute was given fifteen days to identify the steps it would take to prevent future violations.
Another warning issued in October 2012 notes that the Burzynski Clinic is advertising investigational drugs as being "safe and effective", noting:
Promotion of an investigational new drug is prohibited under FDA regulations at 21 CFR 312.7(a), which states, "A sponsor or investigator, or any person acting on behalf of a 1 sponsor or investigator, shall not represent in a promotional context that an investigational new drug is safe or effective for the purposes for which it is under investigation or otherwise promote the drug. This provision is not intended to restrict the full exchange of scientific information concerning the drug, including dissemination of scientific findings in scientific or lay media. Rather, its intent is to restrict promotional claims of safety or effectiveness of the drug for a use for which it is under investigation and to preclude commercialization of the drug before it is approved for commercial distribution."
The websites, including the posted press releases and embedded videos, contain claims such as the following that promote Antineoplastons as safe and/or effective for the purposes for which they are being investigated or otherwise promote the drugs. [...] Since Antineoplastons are investigational new drugs, the products' indication(s), warnings, precautions, adverse reactions, and dosage and administration have not been established and are unknown at this time. Promoting Antineoplastons as safe and effective for the purposes for which they are under investigation, by making representations such as those noted above, is in violation of 21 CFR 312.7(a).
— FDA enforcement letter, Original
The letter requires cessation of noncompliant promotional activities, including use of testimonials and promotional interviews with Burzynski himself.
In June 2012, antineoplaston trials were paused following the death of a child patient. In January and February 2013, the FDA inspected Burzynski and his IRB in Houston. In December 2013, the FDA issued its findings in warning letters to Burzynski, expressing "concerns about subject safety and data integrity, as well as concerns about the adequacy of safeguards in place at your site to protect patients...."
In November 2013 the FDA released the observational notes from an inspection of Burzynski as a principal investigator that took place between January and March 2013. Among the findings were “[failure] to comply with protocol requirements related to the primary outcome, therapeutic response [...], for 67% of study subjects reviewed during the inspection,” admitting patients who failed to meet inclusion criteria, failing to stop treatment when patients had severe toxic reactions to antineoplastons, and failure to report all adverse events. Further, the FDA told Burzynski, "You failed to protect the rights, safety, and welfare of subjects under your care. Forty-eight (48) subjects experienced 102 investigational overdoses between January 1, 2005 and February 22, 2013 [...] There is no documentation to show that you have implemented corrective actions during this time period to ensure the safety and welfare of subjects.” The FDA also observed that Burzynski had denied patients informed consent by not informing them of extra costs that they might incur during treatment and that he could not account for his stock of the investigational drug. Lastly, the FDA observed: "Your [...] tumor measurements initially recorded on worksheets at baseline and on-study treatment [...] studies for all study subjects were destroyed and are not available for FDA inspectional review", meaning that there was no way for the FDA to verify either initial tumor sizes or effects that the antineoplastons may have had.
In Burzynski's written response to the 2013 FDA investigation he states that the investigators '"complied with all criteria for evaluation of response and made accurate assessments for tumor response."'
In December 2013, the FDA issued two warning letters, one to the Burzynski Institutional Review Board and one to Burzynski, the subjects of the investigations in February. The FDA found that Burzynski and the IRB had largely failed to address the concerns identified in the initial observation reports. The letter to Burzynski noted serious problems with patient medical files with respect to a pediatric patient who died while treated by Burzynski and whose death apparently initiated the investigation.
On March 23, 2014, USA Today reported that the FDA had decided to permit "a handful" of cancer patients to receive Burzynski's treatment provided that the patients did not receive the treatment directly from him.
David Gorski has written that over four decades the FDA and state medical boards have been unable to shut down Burzynkski's business selling unproven treatments – "these organizations are supposed to protect the public from practitioners like Burzynski, but all too often they fail at their charges, in this case spectacularly."
Texas Medical Board
In July 2014, the Texas Medical Board filed a 202-page complaint against Burzynski to the Texas State Office of Administrative Hearings. The complaint addresses allegations by the Board including misleading patients into paying exorbitant charges,:2 misrepresenting unlicensed persons to patients as licensed medical doctors,:2,4-6,28-31,50-53 and misleading patients into accepting care from providers without significant education or training related to cancer treatment.:2 Citing examples of problems with 29 patients, which are listed in the document, the board said that "unapproved combinations of highly toxic chemotherapy" were prescribed "in ways that caused harm to several patients."
The use of chemotherapuetic agents by the clinic has been characterized as "random" and their use of unapproved combinations "with no known benefits but clear harms" by the Texas Medical Board, which regulates and licenses physicians in the state of Texas, led to a case against Burzynski by the Texas Medical Board. Burzynski was acquitted because he had not personally written the prescriptions.
In 1994, a court found against Burzynski in a case of insurance fraud. According to the SMU Law Review, Burzynski was found to have defrauded an ERISA health insurance fund by billing it for unapproved "treatment" with antineoplastons, in violation of the terms of the health plan it covered.
In December 2010, the Texas State Board of Medical Examiners filed a multi-count complaint against Burzynski for failure to meet state medical standards. This suit was eventually withdrawn in November 2012 after the judge allowed Burzynski to repudiate responsibility for the actions of staff at the clinic. An appeal against the advertising restrictions on the grounds of free speech was denied on the basis that this was commercial speech promoting an unlawful activity.
In January 2012, Lola Quinlan, an elderly, stage IV cancer patient, sued Burzynski for using false and misleading tactics to "swindle her out of $100,000". She also sued his companies, The Burzynski Clinic, the Burzynski Research Institute and Southern Family Pharmacy, in Harris County Court. She sued for negligence, negligent misrepresentation, fraud, deceptive trade and conspiracy.
Legal threats to online critics
In November 2011, a music writer and editor for the British newspaper The Observer sought help raising £200,000 to have his 4-year-old niece, who was diagnosed with glioma, treated at the Burzynski Clinic. Several bloggers reported other cases of patients who had spent similar amounts of money on the treatment, and had died, and challenged the validity of Burzynski's treatments. Marc Stephens, identifying himself as a representative of the Burzynski Clinic, sent emails accusing them of libel and demanding that coverage of Burzynski be removed from their sites. One of the bloggers who received threatening e-mails from Stephens was Rhys Morgan, a 17-year-old sixth-form student from Cardiff, Wales, at the time, previously noted for exposing the Miracle Mineral Supplement. Another was Andy Lewis, a skeptic and publisher of the Quackometer blog.
Following the publicity fallout resulting from the legal threats made by Stephens against the bloggers, the Burzynski Clinic issued a press release on November 29, 2011 confirming that the Clinic had hired Stephens "to provide web optimization services and to attempt to stop the dissemination of false and inaccurate information concerning Dr. Burzynski and the Clinic", apologizing for comments made by Stephens to bloggers and for the posting of personal information, and announcing that Stephens "no longer has a professional relationship with the Burzynski Clinic."
The story, including the threats against the bloggers, was covered by the BMJ (formerly the British Medical Journal). The chief clinician at Cancer Research UK expressed his concern at the treatment offered, and Andy Lewis of Quackometer and science writer Simon Singh, who had previously been sued by the British Chiropractic Association, said that English libel law harms public discussion of science and medicine, and thus public health.
In an article in Skeptical Inquirer published in March 2014, skeptic Robert Blaskiewicz chronicled the activities by skeptics to investigate and challenge Burzynski's claim of cancer treatments. He claimed aggressive actions by Burzynski's supporters toward the critics, including contacting their employers, lodging complaints to state licensing boards and defamation. Blaskiewicz pointedly indicated that, although Burzynski had dismissed Marc Stephens, his clinic has not retracted the warnings of the possibility of lawsuits against critics, that it is "a threat that hangs over all of these activists every day".
Media and commentary
- In 2010, Eric Merola, an art director of television commercials, released a film titled Burzynski: Cancer is Serious Business, that promotes the Clinic's claims and describes Burzynski's use of antineoplastons and his legal clashes with government agencies and regulators. In March 2013, Merola released a follow-up movie to Cancer is Serious Business. The Village Voice commented that the first movie "violates every basic rule of ethical filmmaking" and that by interviewing only Burzynski's supporters, the film's producer "is either unusually credulous, or doesn't understand the difference between a documentary and an advertisement". Variety described the film as having the qualities of a "paranoid conspiracy theory" and likened it to the National Enquirer, adding that the film's explanatory diagrams are "simplistic to the point of idiocy". The Variety review concluded, however, "Despite its infotainment look, Burzynski ultimately proves convincing."
- In April 2013, Burzynski received the Pigasus Award, which is bestowed each April Fool's Day by the James Randi Educational Foundation (JREF) to "honor the five worst offenders who are intentionally or unintentionally peddling harmful paranormal and pseudoscientific nonsense." The Foundation cited as the basis for the award the high cost of antineoplaston treatments, the lack of controlled trials demonstrating efficacy, the lack of FDA approval on the treatments, the lack of published final results of any single clinical trial, and the existence of FDA warning letters concerning research method safety and possible rules violations impacting patient safety.
- In June 2013, the BBC's Panorama explored Burzynski in a documentary titled Curing cancer or 'selling hope' to the vulnerable? and argued "Burzynski exploits a legal loophole" by treating patients with antineoplastons "as part of a clinical trial, so the drug does not need a licence" for twenty years. The clinic complained to the Office of Communications (Ofcom) about the documentary, but the complaint was not upheld.
- In November 2013, an investigative report in USA Today by Liz Szabo accused Burzynski of selling "false hope to families" for years. In an interview with Reporting on Health, Szabo said that her interest in reporting on Burzynski was sparked when she emailed him with questions asking for a response to a book critical of him, and received a legal warning letter from his attorneys in reply.
- Smith, Murray E. G. (1992). "The Burzynski Controversy in the United States and in Canada: A Comparative Case Study in the Sociology of Alternative Medicine". The Canadian Journal of Sociology 17 (2). doi:10.2307/3341192.
- "Unproven Methods of Cancer Management — Antineoplastons". CA: A Cancer Journal for Clinicians 33 (1): 57–59. 1983. doi:10.3322/canjclin.33.1.57. PMID 6401577.
- Smith, p. 136 "he earned his Ph.D. in biochemistry with a thesis entitled 'Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency'."
- "Burzynski Research Institute Home Page". Retrieved May 10, 2007.
- Vickers, A. (2004). "Alternative Cancer Cures: 'Unproven' or 'Disproven'?". CA 54 (2): 110–8. doi:10.3322/canjclin.54.2.110. PMID 15061600.
- Di Rocco, C (December 2014). "Main editor's comment to the paper: the response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Stanislaw R. Burzynski, Tomasz J. Janicki, Gregory S. Burzynski, Ania Marszalek." (PDF) 30 (12). Childs Nerv Syst (Springer). p. 2063. doi:10.1007/s00381-014-2513-5. PMID 25096071.
- Blaskiewicz, Robert (24 July 2014). "Comment to the paper: The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma" (PDF). Childs Nerv Syst (Springer). doi:10.1007/s00381-014-2514-4. PMID 25146834.
- Block, Keith I. (2004). "Antineoplastons and the Challenges of Research in Integrative Care". Integrative Cancer Therapies 3 (1): 3–4. doi:10.1177/1534735404263274. PMID 15035867.
- Brownlee, Shannon; Cohen, Gary (1998). "Trials of a Cancer Doc: Experimental drugs and a 20-year fight with the FDA". US News & World Report 125 (13): 28–30, 32, 35. PMID 10186429.
- National Cancer Institute Information for Patients: Antineoplastons (PDQ®): Questions and Answers About Antineoplastons Updated: April 9, 2013. Page accessed March 14, 2015.
- The Lancet (1997). "Lessons from antineoplaston". Lancet 349 (9054): 741. doi:10.1016/S0140-6736(97)21011-1. PMID 9091754.
- Burzynski, S. R.; Janicki, T. J.; Weaver, R. A.; Burzynski, B. (2006). "Targeted Therapy with Antineoplastons A10 and AS2-1 of High-Grade, Recurrent, and Progressive Brainstem Glioma". Integrative Cancer Therapies 5 (1): 40–47. doi:10.1177/1534735405285380. PMID 16484713.
- Burzynski, SR (1986). "Antineoplastons: history of the research (I)". Drugs under experimental and clinical research 12 (Suppl 1): 1–9. PMID 3527634.
- Marshall, Eliot (1994). "The Politics of Alternative Medicine". Science 265 (5181): 2000–2002. doi:10.1126/science.8091220. PMID 8091220.
- NCI Drug Dictionary, Definitions of antineoplastons A10 and AS2-1
- Dr. Stanislaw Burzynski's "personalized gene-targeted cancer therapy": Can he do what he claims for cancer?, David Gorski, Science Based Medicine
- David Gorski for Science-Based Medicine. December 12, 2011 Dr. Stanislaw Burzynski, antineoplastons, and the selling of an orphan drug as a cancer cure Quote: " it’s not the concept of “personalized gene-targeted therapy” to which I object. It’s how Burzynski does it and how he corrupts the very concept through his “everything but the kitchen sink” approach to throwing “targeted” therapies at cancer patients willy-nilly without a systematic rationale for picking them or, it seems, any concern for potential adverse reactions due to combining drugs that have not been tested adequately in combination."
- Sharon Hill for The Skeptical Inquirer. January 10, 2014 Burzynski Clinic: A Scientifical Year Of Fail
- National Cancer Institute. Information for Professionals: Antineoplastons (PDQ®): Human/Clinical Studies Updated: April 9, 2013. Page accessed March 14, 2015.
- National Cancer Institute. Information for Professionals: Antineoplastons (PDQ®): Summary of the Evidence Updated: April 9, 2013. Page accessed March 14, 2015.
- Four decades of an unproven cancer cure, David Gorski, Skeptical Inquirer vol 38.2, April 2014, Center for Inquiry
- A Film Producer, A Cancer Doctor, And Their Critics, Peter Lipson, Forbes, 2013-19-04
- Jaffe, Richard (2008). Galileo's Lawyer: Courtroom Battles in Alternative Health, Complementary Medicine and Experimental Treatments. Houston, TX: Thumbs UP. p. 107. ISBN 978-0980118308.
- Szabo, Liz (November 15, 2013). "Doctor accused of selling false hope to families". USA Today. Retrieved November 15, 2013.
- "Antineoplaston Therapy". American Cancer Society. November 2008. Retrieved January 2013.
- "What is antineoplaston therapy?". Cancer Research UK. Retrieved November 25, 2011.
- National Cancer Institute. Information for Professionals: Antineoplastons (PDQ®): Overview Updated: April 9, 2013. Page accessed March 14, 2015.
- "Antineoplastons". CA 33 (1): 57–9. 1983. doi:10.3322/canjclin.33.1.57. PMID 6401577.
- Langford, Terri (October 1, 1998). "Oncologists criticize methods of controversial cancer treatment". Associated Press.
- "The Antineoplaston Anomaly: How a Drug Was Used for Decades in Thousands of Patients, With No Safety, Efficacy Data". The Cancer Letter. September 25, 1998. Retrieved August 26, 2012.
- Antineoplastons, Memorial Sloan-Kettering Cancer Center
- Burzynski Clinic Preparing for your appointment Page accessed March 15, 2014
- Texas State Board of Medical Examiners, Appellant v. Stanislaw R. Burzynski, M.D., Ph.D., Appellee Court judgement
- 819 F.2d 1301 1987 judgment
- "2009 Burzynski Research Institute Warning Letter". U.S. Food and Drug Administration. Retrieved November 22, 2011.
- Respectful Insolence, ScienceBlogs, November 7, 2012
- Szabo, Liz (December 11, 2013). "FDA issues warning to controversial Houston cancer doctor". USA Today. Retrieved March 14, 2015.
- Lipson, Peter. "FDA Documents Paint Disturbing Picture of Burzynski Cancer Clinic". Forbes. Retrieved November 14, 2013.
- Gorski, David. "Revealed by the FDA: The results of the most recent inspection of the Burzynski Clinic". Science Based Medicine. Retrieved November 14, 2013.
- FDA Inspection Letter 
- Szabo, Liz (December 11, 2013). "FDA issues warning to controversial Houston cancer doctor". USA Today. Retrieved December 12, 2013.
- "Inspections, Compliance, Enforcement, and Criminal Investigations". FDA. Retrieved December 12, 2013.
- Gorski D (2014). "Stanislaw Burzynski: four decades of an unproven cancer cure". Skeptical Inquirer 38 (2): 36.
- Hearing Conducted by the Texas State Office of Administrative hearings, Texas Medical Board, July 10, 2014 SOAH Docket No. 503-12-1342
- Brooks, David (July 14, 2014). "Texas Medical Board files 202-page complaint against cancer "cure" being used in NH". Nashua Telegraph. Retrieved July 20, 2014.
- Szabo, Liz (July 24, 2014). "Texas medical board charges controversial cancer doctor". USA Today. Retrieved July 24, 2014.
- "SMU Law Review: A Publication of Southern Methodist University School of Law". SMU law review (Southern Methodist University School of Law) 50 (2): 1293. 1997. ISSN 1066-1271.
- Texas State Office of Administrative Hearings via Stanislaw Burzynski gets off on a technicality, National Geographic ScienceBlogs
- Cameron Langford. "Cancer Patient Says Doc Used Her as ATM." Courthouse News Service, January 19, 2012
- Luke Bainbridge (November 20, 2011). ""The worst year of my life: cancer has my family in its grip" Luke Bainbridge. 20 November 2011". London: Guardian. Retrieved July 19, 2013.
- Stanislaw Burzynski's public record, Skeptical Humanities
- Burzynski clinic the domain of scoundrels and quacks, Pharyngula (PZ Myers)
- "Burzynski Clinic? Meet the Streisand Effect". Retrieved November 28, 2011.
- Sample, Ian (November 29, 2011). "The schoolboy blogger who took on a US clinic". The Guardian (London). Retrieved November 29, 2011.
- Malisow, Craig (November 29, 2011). "Burzynski Fanatic Threatens Bloggers 'Round the World". Houston Press. Retrieved November 29, 2011.
- Plait, Phil (November 28, 2011). ""Alternative" cancer clinic threatens to sue high school blogger". Discover Magazine. Retrieved November 29, 2011.
- Morgan, Rhys (November 20, 2011). "The Burzynski Clinic is using libel laws to silence critics of its cancer treatment". The Guardian (London). Retrieved November 20, 2011.
- Robbins, Martin (September 15, 2010). "The man who encourages the sick and dying to drink industrial bleach". The Guardian (London). Retrieved December 1, 2011.
- "The man who encourages the sick and dying to drink industrial bleach". The Richard Dawkins Foundation for Reason and Science. October 17, 2010. Retrieved December 1, 2011.
- The Burzynski clinic: another crank tries to intimidate a blogger, Steve Novella
- "Threats From The Burzynski Clinic".
- Burzynski clinic threatens my family, The Quackometer
- "Press Release". Burzynski Clinic. Retrieved November 29, 2011.
- McCartney, M. (2011). "Texan clinic threatens UK bloggers with legal action over criticisms of its treatments". BMJ 343: d7865. doi:10.1136/bmj.d7865. PMID 22138837.
- Blaskiewicz, Robert (2014). "Skeptic Activists Fighting for Burzynski’s Cancer Patients". Skeptical Inquirer (CSI) 38.2 (March/April): 44–47.
- Catsoulis, Jeannette (June 4, 2010). "A Texas Doctor With a Possible Cancer Cure". New York Times. Burzynski at the Internet Movie Database
- Joanne Ostrow (August 21, 2009). "KBDI pushes limits on controversial pledge tie-ins". DenverPost.com. Retrieved November 14, 2013.
- Ella Taylor (June 1, 2010). "QUACK-QUACK Goes Burzynski - Page 1 - Movies - New York". Village Voice. Retrieved November 25, 2011.
- Scheib, Ronnie (June 3, 2010). "Variety Reviews - Burzynski - Film Reviews - New U.S. Release - Review by Ronnie Scheib". Variety.com. Retrieved November 25, 2011.
- "JREF's Pigasus Awards "Honors" Dubious Peddlers of "Woo"". James Randi Educational Foundation. Retrieved April 1, 2013.
- Richard Bilton (August 22, 2013). "Curing cancer or 'selling hope' to the vulnerable?". Panorama (TV series). Retrieved June 2013.
- "Amelia's family 'mislead by cancer clinic'". Reading Post. August 22, 2013. Retrieved June 2013.
- "Ofcom Broadcast Bulletin" (PDF). Issue number 243. December 2, 2013. Retrieved December 2, 2013.
- Szabo, Liz (November 15, 2013). "Doctor accused of selling false hope to families". USA Today. Updated July 8, 2014. Retrieved December 12, 2013.
- "Braving legal threats to investigate a medical folk hero". Reporting on Health.
- Gorski D (14 March 2013). "Burzynski: Cancer Is A Serious Business, Part 2: Like the first Burzynski movie, only more so?". Science-Based Medicine. Retrieved March 2015.
- Green S (19 January 2013). "Stanislaw Burzynski and 'Antineoplastons'". Quackwatch. Retrieved March 2015.